Nxera Pharma (4565) investor relations material

Executive summary

• Revenue rose 69.4% year-over-year to JPY 11,256 million for Q1 2026, driven by strong milestone revenues and growth in marketed products.

• Net profit reached JPY 1,793 million, reversing a net loss of JPY 760 million in Q1 2025.

• Major operational highlights included new licensing agreements, positive clinical trial results, and significant milestone payments from partners.

Financial highlights

• Core operating profit was JPY 5,495 million, up from a core operating loss of JPY 625 million year-over-year.

• Operating profit improved to JPY 3,244 million from a loss of JPY 2,193 million.

• Gross profit margin increased, with cost of sales down by JPY 497 million.

• R&D expenses decreased by JPY 780 million, reflecting a streamlined focus and program maturation.

• SG&A expenses fell by JPY 131 million due to cost reduction initiatives.

Outlook and guidance

• FY2026 revenue forecast: JPY 33,800–48,800 million; core operating profit: JPY 7,800–22,800 million.

• Product revenue for PIVLAZ® projected at JPY 13,800–14,200 million; QUVIVIQⓇ at JPY 5,000–6,000 million.

• Assumes JPY 12,500 million in milestone income and JPY 3,500 million cost base reduction.